Phio Pharmaceuticals Corp. (PHIO)
0.808
+0.01
(+1.00%)
USD |
NASDAQ |
Nov 06, 10:23
Phio Pharmaceuticals EPS Diluted (Quarterly) : -0.3562 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.3562 |
| March 31, 2026 | -0.3446 |
| December 31, 2025 | -0.2041 |
| September 30, 2025 | -0.4374 |
| June 30, 2025 | -0.4517 |
| March 31, 2025 | -0.4107 |
| December 31, 2024 | -0.9379 |
| September 30, 2024 | -1.539 |
| June 30, 2024 | -3.618 |
| March 31, 2024 | -4.233 |
| December 31, 2023 | -4.551 |
| September 30, 2023 | -10.25 |
| June 30, 2023 | -13.27 |
| March 31, 2023 | -28.38 |
| December 31, 2022 | -21.58 |
| September 30, 2022 | -28.27 |
| June 30, 2022 | -20.01 |
| March 31, 2022 | -21.04 |
| December 31, 2021 | -27.54 |
| September 30, 2021 | -29.86 |
| June 30, 2021 | -21.44 |
| March 31, 2021 | -34.45 |
| December 31, 2020 | -46.00 |
| September 30, 2020 | -43.14 |
| June 30, 2020 | -36.36 |
| Date | Value |
|---|---|
| March 31, 2020 | -143.21 |
| December 31, 2019 | -506.38 |
| September 30, 2019 | -489.52 |
| June 30, 2019 | -498.96 |
| March 31, 2019 | -616.39 |
| December 31, 2018 | -600.59 |
| September 30, 2018 | -2028.81 |
| June 30, 2018 | -2752.48 |
| March 31, 2018 | -5331.68 |
| December 31, 2017 | -4997.92 |
| September 30, 2017 | -6255.41 |
| June 30, 2017 | -6670.03 |
| March 31, 2017 | -15765.95 |
| December 31, 2016 | -35640.00 |
| September 30, 2016 | -20196.00 |
| June 30, 2016 | -20196.00 |
| March 31, 2016 | -20196.00 |
| December 31, 2015 | -23760.00 |
| September 30, 2015 | -23760.00 |
| June 30, 2015 | -29700.00 |
| March 31, 2015 | -77220.00 |
| December 31, 2014 | -77220.00 |
| September 30, 2014 | -100980.0 |
| June 30, 2014 | -136620.0 |
| March 31, 2014 | -190080.0 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| CapForce, Inc. | 3.384 |
| Agenus, Inc. | -0.0146 |
| Amgen, Inc. | 7.077 |
| Anika Therapeutics, Inc. | 0.2412 |
| BioCryst Pharmaceuticals, Inc. | 0.1417 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -4.138M |
| Total Expenses (Quarterly) | 4.138M |
| Enterprise Value | -3.702M |
| Earnings Yield | -166.1% |
| Normalized Earnings Yield | -166.13 |